TEZSPIRE is the brand name for tezepelumab-ekko, a thymic stromal lymphopoietin (TSLP) blocker and human monoclonal antibody. It is formulated as an injection for subcutaneous administration, supplied in single-dose vials, pre-filled syringes, or pens, each containing 210 mg of the active ingredient per 1.91 mL. Key inactive ingredients include glacial acetic acid, L-proline, polysorbate 80, and sodium hydroxide.
How should I use this medication?
This medication is injected under the skin. It is given by your care team in a hospital or clinic setting. It may also be given at home. If you get this medication at home, you will be taught how to prepare and give it. Use exactly as directed. Take it as directed on the prescription label at the same time every day. Keep taking it unless your care team tells you to stop If you use a pen, be sure to take off the outer needle cover before using the dose. It is important that you put your used needles and syringes in a special sharps container. Do not put them in a trash can. If you do not have a sharps container, call your pharmacist or care team to get one. Talk to your care team about the use of this medication in children. While it may be prescribed for children as young as 12 years for selected conditions, precautions do apply.
Overdosage: If you think you have taken too much of this medicine contact a poison control center or emergency room at once. NOTE: This medicine is only for you. Do not share this medicine with others.
What if I miss a dose?
Keep appointments for follow-up doses. It is important not to miss your dose. Call your care team if you are unable to keep an appointment.
Where should I keep my medication?
Keep out of the reach of children and pets. This medication may be given in a hospital or clinic. If it is used at home, store in a refrigerator or at room temperature between 20 and 25 degrees C (68 and 77 degrees F). Refrigeration (preferred): Store it in the refrigerator. Keep it in the original carton until you are ready to take it. Get rid of any unused medication after the expiration date. Room Temperature: This medication may be stored at room temperature for up to 30 days. Do not put the medication back into the refrigerator once it has reached room temperature. If it is stored at room temperature, get rid of any unused medication after 30 days or after it expires, whichever is first.
NOTE: This sheet is a summary. It may not cover all possible information. If you have questions about this medicine, talk to your doctor, pharmacist, or health care provider.
What side effects may I notice from receiving this medication?
Side effects that you should report to your care team as soon as possible: -Allergic reactions—skin rash, itching, hives, swelling of the face, lips, tongue, or throat Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome): -Back pain -Joint pain -Sore throat
This list may not describe all possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What should I tell my care team before I take this medication?
They need to know if you have any of these conditions: -Parasitic (helminth) infection -An unusual or allergic reaction to tezepelumab, hamster proteins, other medications, foods, dyes, or preservatives -Pregnant or trying to get pregnant -Breast-feeding
What may interact with this medication?
Interactions are not expected.
This list may not describe all possible interactions. Give your health care provider a list of all the medicines, herbs, non-prescription drugs, or dietary supplements you use. Also tell them if you smoke, drink alcohol, or use illegal drugs. Some items may interact with your medicine.
What should I watch for while using this medication?
Visit your care team for regular checks on your progress. Tell your care team if your symptoms do not start to get better or if they get worse. Talk to your care team about how to treat an acute asthma attack or bronchospasm (wheezing). Be sure to always have a short-acting inhaler with you. If you use your short-acting inhaler and your symptoms do not get better or if they get worse, call your care team right away. You and your care team should develop an Asthma Action Plan that is just for you. Be sure to know what to do if you are in the yellow (asthma is getting worse) or red (medical alert) zones.
Source: This information is sourced from Elsevier Inc.
The reviews, ratings, comments, and opinions expressed on this platform are solely those of the individual medical professionals who posted them and do not reflect the views or positions of Sermo, Inc. Sermo does not endorse, verify, or validate the content of individual reviews. The information provided is user-generated and reflects personal clinical experiences, which may not be complete, accurate, or applicable to your specific health needs. It is not intended as medical advice.
Prescription medications affect individuals differently, and what works for one person may not work for another. Always consult your doctor, pharmacist, or other qualified healthcare provider to ensure the information displayed applies to your personal circumstances. Only a licensed healthcare provider can advise you on what is safe and effective for you.
Keep all medications out of the reach of children, never share your medicine with others, and use each medication only as prescribed. Your reliance on any information provided on this platform is at your own risk.
Sermo Drug Ratings, and all information provided on this website, may not be used in combination with any artificial intelligence tool (including to train an algorithm, test, process, analyze, generate output and/or develop any form of artificial intelligence tool).
Visitors to the online patient-facing website at Sermo.com (“Sermo Drug Ratings”) are Authorized Users of the website, which contains data owned by a third-party provider, Elsevier, Inc. Accordingly, by visiting Sermo Drug Ratings, Authorized User acknowledges that the website includes Elsevier owned data that Sermo licenses pursuant to a separate usage and Data agreement (the “Agreements”). Authorized User further acknowledges that Sermo is a third-party beneficiary of the Agreements and Authorized User’s use of the website hereby binds them to the terms of the Agreements; provided, however, that Elsevier shall have no obligations or liability to an Authorized User whatsoever pursuant to the terms of the Agreements.